tm logo
Trademark Search
KYVERNA TAMING AUTOIMMUNITY & DESIGN
KYVERNA TAMING AUTOIMMUNITY & DESIGN
SEARCHED

on 26 Jun 2024

Last Applicant/ Owned by

KYVERNA THERAPEUTICS INC.

5980 Horton StreetSuite 550Emeryville, CA 94608

US

Serial Number

2117748 filed on 30th Jun 2021

Correspondent Address

SUITE 16001 FIRST CANADIAN PLACE100 KING STREET WESTTORONTO

ONTARIO

CA

M5X1G5

KYVERNA TAMING AUTOIMMUNITY & DESIGN

Vienna Information


24 . 13 . 1

Greek cross, St. Andrew's crossCroix grecque ou de Saint-André

24 . 13 . 21

Crosses with rays or radiating linesCroix avec rayonnement

1 . 1 . 1

StarsÉtoiles

1 . 1 . 2

One starUne étoile

1 . 1 . 10

Stars with more than four pointsÉtoiles à plus de quatre pointes

1 . 1 . 12

Stars with uneven points -- Note: Including sparks consisting of uneven-pointed stars.Étoiles à pointes irrégulières -- Note: Y compris les étincelles constituées d'étoiles à pointes irrégulières.

1 . 15 . 7

Sparks, explosions, exploding fireworks -- Note: Not including sparks represented by uneven-pointed stars (1.1.1).Étincelles, explosions, feux d'artifice -- Note: Non compris les étincelles constituées d'étoiles à pointes irrégulières (1.1.1).

1 . 1 . 13

Stars with rays or radiating linesÉtoiles avec rayonnement

25 . 12 . 1

Surfaces or backgrounds covered with rays or radiating linesSurfaces ou fonds rayonnés

Trademark usage description

pharmaceuticals; pharmaceutical preparations; pharmaceutical therapeutic agents for medical use; therapeutic pharmaceutical for the treatment of autoi Read More

Classification Information


Class [001]
Chemicals and adhesives


Comment text

CIPO Classification Code

Classification kind code

Nice

Class [005]
Pharmaceuticals; pharmaceutical preparations; pharmaceutical therapeutic agents for medical use; therapeutic pharmaceutical for the treatment of autoimmune disease; therapeutic pharmaceuticals and cell therapy products in the nature of cells for medical or clinical use for the treatment of autoimmune disease; cell therapy products, namely, genetically engineered immune cells for medical or clinical use for the treatment of autoimmune disease; cell therapy products for the treatment of autoimmune disease; cells for medical use; living cells for medical use; cell therapy products, namely, genetically engineered immune cells for the treatment of autoimmune disease; antibodies; antibody receptors; antigens; antigen receptors; diagnostic agents, preparations and substances for medical purposes; pharmaceutical products, namely, diagnostic reagents for medical purposes; control reagents for medical laboratory purposes; control reagents for clinical medical purposes


Classification kind code

11

Class [042]
Scientific and technological services and research and design relating thereto; industrial analysis and research services; research, development, testing and evaluation of pharmaceuticals, pharmaceutical preparations and pharmaceutical therapeutic agents; research, development, testing and evaluation of medical preparations, cells for medical use, antibodies, antibody receptors, antigens and antigen receptors; medical research and development; research, development, testing and evaluation of diagnostic agents, preparations and substances for medical purposes; medical and scientific research and development in the field of diagnosis and treatment of autoimmune disease; information, advice and consultancy regarding the aforementioned services


Classification kind code

11

Class [044]
Medical services; medical information services; medical testing services; medical diagnostic testing services; medical treatment services; medical services, namely, cell based therapies; medical services for the diagnosis and treatment of autoimmune disease; medical services, namely, cell based therapies; information, advice and consultancy regarding the aforementioned services


Classification kind code

11

Mark Details


Serial Number

2117748

Mark Type

Trademark

Legal History


Action TakenStatus
Submitted for opposition 22
on 26th Jun 2024
Search Recorded
Submitted for opposition 20
on 26th Jun 2024
Examiner's First Report
Submitted for opposition 287
on 12th May 2022
Pre-Assessment Letter Sent
Submitted for opposition 30
on 30th Jun 2021
Filed
Submitted for opposition 1
on 30th Jun 2021
Created
Submitted for opposition 31
on 30th Jun 2021
Formalized